Compare Heron Therapeutics Inc (HRTX) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs ProShares Ultra Gold ETF — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while ProShares Ultra Gold ETF trades at $46.5 (market cap $715.43M). The key difference: ProShares Ultra Gold ETF is far larger — about 9.7× Heron Therapeutics Inc's market cap, and Heron Therapeutics Inc is more actively traded (3,668,095 versus 3,002,043). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and ProShares Ultra Gold ETF for 23 Days on average.
| HRTX | UGL | |
|---|---|---|
Market Cap | $74.04M | $715.43M |
Volume | 3,668,095 | 3,002,043 |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.49 | $85.62 |
52-Week Low | $0.27 | $42.79 |
Typical Hold Time | 35 Days | 23 Days |
Enterprise Value | $180.78M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
UGL stock is trading at $44.43, down 3.29% over the past day amid a broader bearish technical signal. The stock faces selling pressure with moving averages and oscillators indicating a downtrend, while key support lies at $43. Recent news highlights gold's volatility driven by shifting Federal Reserve rate expectations and Treasury yield movements, impacting sentiment.
The outlook remains cautious with technical indicators signaling bearish momentum, though oversold conditions on the 12-day RSI may offer short-term relief. Risks include persistent macroeconomic headwinds from interest rates and dollar strength, while the lack of available fundamental data limits visibility on the company's financial health and valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
